Skip to main content
. 2013 Jan 8;18(1):27–36. doi: 10.1634/theoncologist.2011-0380

Table 6.

Cost-effectiveness of VMP versus MP, VMP versus MPT, and VMP versus MPR-R over a 20-year lifetime horizon

graphic file with name onc00113-1138-t06.jpg

Abbreviations: LY, life year; MP, melphalan and prednisone; MPR-R, MP plus lenalidomide with lenalidomide maintenance; MPT, MP plus thalidomide; QALY, quality-adjusted life year; VMP, bortezomib plus MP.